Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes

The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also revolutionized the treatment options for other B cell malignancies. Increasing evidence indicates that in addition to their...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Sining, Gokhale, Samantha, Jung, Jaeyong, Spirollari, Eris, Tsai, Jemmie, Arceo, Johann, Wu, Ben Wang, Victor, Eton, Xie, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414982/
https://www.ncbi.nlm.nih.gov/pubmed/34485307
http://dx.doi.org/10.3389/fcell.2021.727531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414982/
https://www.ncbi.nlm.nih.gov/pubmed/34485307
http://dx.doi.org/10.3389/fcell.2021.727531

Ejemplares similares